Paromomycin

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 103, Issue 7, 2009, Pages 653-660

  Davidson, Robert N ^a   den Boer, Margriet ^b   Ritmeijer, Koert ^b  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Aminoglycosides; Aminosidine; Combination drug therapy; Cutaneous leishmaniasis; Paromomycin; Visceral leishmaniasis

Indexed keywords

DIURETIC AGENT; KETOCONAZOLE; METHYLBENZETHONIUM CHLORIDE; PAROMOMYCIN; PLACEBO; STIBOGLUCONATE SODIUM;

ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; EDEMA; ERYTHEMA; HEARING LOSS; HUMAN; LACTATION; LIVER TOXICITY; MONOTHERAPY; MYALGIA; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; OUTCOME ASSESSMENT; PRURITUS; REVIEW; SIDE EFFECT; SKIN LEISHMANIASIS; STRUCTURE ANALYSIS; TREATMENT DURATION; URETHRITIS; VESTIBULAR DISORDER; VISCERAL LEISHMANIASIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIPROTOZOAL AGENTS; COMMUNICABLE DISEASES, EMERGING; DRUG RESISTANCE; HUMANS; LEISHMANIASIS, VISCERAL; PAROMOMYCIN;

CESTODA; NEGIBACTERIA; POSIBACTERIA; PROTOZOA;

EID: 67349199791     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2008.09.008     Document Type: Review

References (51)

1. Kellina O.I. A study of experimental cutaneous leishmaniasis in white mice [in Russian]. Med Parazitol (Mosk) 30 (1961) 684-691
2. Neal R.A. The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis. Ann Trop Med Parasitol 62 (1968) 54-62
3. Neal R.A., Allen S., McCoy N., Olliaro P., and Croft S.L. The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 35 (1995) 577-584
4. Chunge C.N., Owate J., Pamba H.O., and Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 84 (1990) 221-225
5. Scott J.A., Davidson R.N., Moody A.H., Grant H.R., Felmingham D., Scott G.M., et al. Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom. Trans R Soc Trop Med Hyg 86 (1992) 617-619
6. Thakur C.P., Olliaro P., Gothoskar S., Bhowmick S., Choudhury B.K., Prasad S., et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 86 (1992) 615-616
7. Seaman J., Pryce D., Sondorp H.E., Moody A., Bryceson A.D., and Davidson R.N. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 168 (1993) 715-720
8. Gutteridge W.E. TDR collaboration with the pharmaceutical industry. Trans R Soc Trop Med Hyg 100 Suppl 1 (2006) S21-S25
9. Thakur C.P., Bhowmick S., Dolfi L., and Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg 89 (1995) 219-223
10. Thakur C.P., Kanyok T.P., Pandey A.K., Sinha G.P., Messick C., and Olliaro P. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 94 (2000) 432-433
11. Thakur C.P., Kanyok T.P., Pandey A.K., Sinha G.P., Zaniewski A.E., Houlihan H.H., et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 94 (2000) 429-431
12. Jha T.K., Olliaro P., Thakur C.P., Kanyok T.P., Singhania B.L., Singh I.J., et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 316 (1998) 1200-1205
13. Kanyok T.P., Reddy M.V., Chinnaswamy J., Danziger L.H., and Gangadharam P.R. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains. Antimicrob Agents Chemother 38 (1994) 170-173
14. Donald P.R., Sirgel F.A., Kanyok T.P., Danziger L.H., Venter A., Botha F.J., et al. Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 44 (2000) 3285-3287
15. Maarouf M., Lawrence F., Brown S., and Robert-Gero M. Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes. Parasitol Res 83 (1997) 198-202
16. Neal R.A., and Croft S.L. An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J Antimicrob Chemother 14 (1984) 463-475
17. Gebre-Hiwot A., Tadesse G., Croft S.L., and Frommel D. An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1. Acta Trop 51 (1992) 237-245
18. Maarouf M., Adeline M.T., Solignac M., Vautrin D., and Robert-Gero M. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite 5 (1998) 167-173
19. Buffet P.A., Garin Y.J., Sulahian A., Nassar N., and Derouin F. Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum. Ann Trop Med Parasitol 90 (1996) 295-302
20. Gangneux J.P., Sulahian A., Garin Y.J., and Derouin F. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum. J Antimicrob Chemother 40 (1997) 287-289
21. Poli A., Sozzi S., Guidi G., Bandinelli P., and Mancianti F. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis. Vet Parasitol 71 (1997) 263-271
22. Vexenat J.A., Olliaro P.L., Fonseca de Castro J.A., Cavalcante R., Furtado Campos J.H., Tavares J.P., et al. Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin). Am J Trop Med Hyg 58 (1998) 448-453
23. Williams D., Mullen A.B., Baillie A.J., and Carter K.C. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. J Pharm Pharmacol 50 (1998) 1351-1356
24. el-On J., Sulitzeanu A., and Schnur L.F. Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment. Ann Trop Med Parasitol 85 (1991) 323-328
25. Fong D., Chan M.M., Rodriguez R., Gately L.J., Berman J.D., and Grogl M. Paromomycin resistance in Leishmania tropica: lack of correlation with mutation in the small subunit ribosomal RNA gene. Am J Trop Med Hyg 51 (1994) 758-766
26. Teklemariam S., Hiwot A.G., Frommel D., Miko T.L., Ganlov G., and Bryceson A. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 88 (1994) 334-339
27. Kanyok T.P., Killian A.D., Rodvold K.A., and Danziger L.H. Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects. Antimicrob Agents Chemother 41 (1997) 982-986
28. Sundar S., Jha T.K., Thakur C.P., Sinha P.K., and Bhattacharya S.K. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356 (2007) 2571-2581
29. Kshirsagar S, Mordenti J, Blaschke T. Clinical pharmacokinetics of paromomycin sulfate in Indian visceral leishmaniasis patients. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 27-30 September 2006; San Francisco, CA. Washington, DC: ASM Press; 2006, poster A-1105.
30. Hassan M., Baat D.B., and Hassan K. A new breakthrough in treatment of visceral leishmaniasis in children. J Pak Med Assoc 45 (1995) 155-157
31. Melaku Y., Collin S.M., Keus K., Gatluak F., Ritmeijer K., and Davidson R.N. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 77 (2007) 89-94
32. Seifert K., and Croft S.L. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 50 (2006) 73-79
33. Soto J., Grogl M., Berman J., and Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 88 (1994) 695-698
34. Hepburn N.C., Tidman M.J., and Hunter J.A. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 88 (1994) 700-703
35. el-On J., Weinrauch L., Livshin R., Even-Paz Z., and Jacobs G.P. Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methylbenzethonium chloride. BMJ 291 (1985) 704-705
36. Asilian A., and Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 31 (2006) 634-637
37. Iraji F., and Sadeghinia A. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran. Ann Trop Med Parasitol 99 (2005) 3-9
38. Shazad B., Abbaszadeh B., and Khamesipour A. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol 15 (2005) 85-87
39. Asilian A., Jalayer T., Nilforooshzadeh M., Ghassemi R.L., Peto R., Wayling S., et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 81 (2003) 353-359
40. Faghihi G., and Tavakoli-kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 28 (2003) 13-16
41. Ben Salah A., Zakraoui H., Zaatour A., Ftaiti A., Zaafouri B., Garraoui A., et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 53 (1995) 162-166
42. el-On J., Halevy S., Grunwald M.H., and Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 27 (1992) 227-231
43. el-Safi S.H., Murphy A.G., Bryceson A.D., and Neal R.A. A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. Trans R Soc Trop Med Hyg 84 (1990) 690-691
44. Asilian A., Jalayer T., Whitworth J.A., Ghasemi R.L., Nilforooshzadeh M., and Olliaro P. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 53 (1995) 648-651
45. Neva F.A., Ponce C., Ponce E., Kreutzer R., Modabber F., and Olliaro P. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin. Trans R Soc Trop Med Hyg 91 (1997) 473-475
46. Arana B.A., Mendoza C.E., Rizzo N.R., and Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 65 (2001) 466-470
47. Moosavi Z., Nakhli A., and Rassaii S. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Int J Dermatol 44 (2005) 1064-1065
48. Armijos R.X., Weigel M.M., Calvopiña M., Mancheno M., and Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop 91 (2004) 153-160
49. Soto J., Fuya P., Herrera R., and Berman J. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 26 (1998) 56-58
50. Ozgoztasi O., and Baydar I. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol 36 (1997) 61-63
51. Khatami A., Firooz A., Gorouhi F., and Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 57 (2007) 335 e1-29